Citations

Showing 10 of 108083 citations.

Acute Kidney Injury in Heart Failure Revisited—The Ameliorating Impact of “Decongestive Diuresis” on Renal Dysfunction in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Naturetic Peptide Is a Predictor of Good Renal Prognosis
Onuigbo, Macaulay , Agbasi, Nneoma, Sengodan, Mohan, Rosario, Karen Flores , Onuigbo, Macaulay Amechi Chukwukadibia, Flores Rosario, Karen

Mayo Clinic

Journal of Clinical Medicine | August 29, 2017 | Volume: 6 | Issue: 9 | Pages: 82

10.3390/jcm6090082 | PMID 28850085 Get It

There is mounting evidence that forward heart failure as manifested by low cardiac output alone does not define the degree of renal dysfunction in cardiorenal syndrome. As a result, the term “congestive renal failure” was coined in 2012 by Ross to depict the role of renal venous hypertension in type 1 acute cardiorenal syndrome. If so, aggressive decongestive therapies, either through mechanical ultrafiltration with dialysis machines or pharmacologic ultrafiltration with potent diuretics, would lead to improved cardio and renal outcomes. Nevertheless, as recently as 2012, a review of this literature had concluded that a renal venous hypertension-directed approach using diuretics to manage cardio-renal syndrome was yet to be fully investigated. We, in this review, with three consecutive case series, describe our experience with pharmacologic decongestive diuresis in this paradigm of care and argue for studies of such therapeutic interventions in the management of cardiorenal syndrome. Finally, based on our observations in the Renal Unit, Mayo Clinic Health System, in Northwestern Wisconsin, we have hypothesized that patients with cardiorenal syndrome presenting with accelerated rising Pro B Naturetic Peptide levels appear to represent a group that would have good cardio- and renal-outcomes with such decongestive pharmacologic therapies.
Six-Month Outcomes for Collaborative Care Management of Depression Among Smoking and Nonsmoking Patients
Witt, Daniel R. , Garrison, Gregory M. , González, César A. , Witt, Terrence J. , Angstman, Kurt B. , Witt, Terrence , Gonzalez, Cesar

Mayo Clinic

Health Services Research and Managerial Epidemiology | August 29, 2017 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/2333392817721648 | PMID 28890910 Get It

Background: Collaborative care management (CCM) is an evidence-based model that contributes to better outcomes for depression treatment in the primary care setting. Tobacco use increases overall economic costs, morbidity, and mortality and has been shown to impact behavioral health outcomes. Our study aims to observe clinical outcomes for depression treatment for patients with comorbid tobacco use and depression within the CCM model. Methods: A retrospective chart review study of 2826 adult patients with depression enrolled in CCM was performed to determine the association between regular tobacco use and depression outcomes. Baseline intake data consisting of clinical and demographic variables along with 6-month follow-up of Patient Health Questionnaire-9 (PHQ-9) scores for smokers (n = 727, 25.7%) and nonsmokers (n = 2099, 74.3%) were obtained. Depression remission was defined as a PHQ-9 score <5 and persistent depressive symptoms (PDS) as a PHQ-9 score ≥10 at 6 months. Results: Using an intention-to-treat analysis, the multivariate modeling demonstrated that smokers, at 6 months, had an increased adjusted odds ratio (AOR) for PDS: 1.624 (95% CI: 1.353-1.949). Furthermore, smokers had a lower AOR of depression remission: 0.603 (95% CI: 0.492-0.739). Patient adherence to treatment was also lower in smokers with an AOR of 0.666 (95% CI: 0.553-0.802). Conclusions: Smokers enrolled in CCM were associated with reduced treatment adherence and worse outcomes for depression treatment at 6 months compared to nonsmokers, even when baseline clinical and demographic variables were controlled. Thus, new tailored practices may be warranted within the CCM model to treat comorbid depression and tobacco use disorders.
Older Adults at Risk for Atrial Fibrillation Lack Knowledge and Confidence to Seek Treatment for Signs and Symptoms
McCabe, Pamela J. , Barton, Debra L. , DeVon, Holli A.

Mayo Clinic

SAGE Open Nursing | August 29, 2017 | Volume: 3 | Issue: No issue available | Pages: No page available

10.1177/2377960817720324 | PMID 30637335 Get It

Early detection of atrial fibrillation (AF) is crucial for averting AF-related stroke and heart failure, but treatment is delayed when AF is not recognized. The critical need for early detection and treatment requires education to promote AF awareness. Knowledge deficits, attitudes, and beliefs about AF that should be addressed to improve awareness and reduce treatment-seeking delay in older adults at risk for developing AF have not been well documented. The purpose of this study was to describe knowledge, treatment-seeking attitudes, and beliefs about AF in adults ≥65 years old and identify demographic characteristics associated with knowledge, attitudes, and beliefs. Patients with no history of AF recruited from an academic medical center were interviewed using the Knowledge, Attitudes, and Beliefs about Atrial Fibrillation Survey. Data were analyzed using descriptive statistics and independent t tests. Participants ( N = 180) were 63% male with a mean age of 73.7 ± 6.0 years, and 52% held ≥ 4-year college degree. About one third could not identify common symptoms of AF including palpitations (31%), chest pain (36%), dyspnea (30%), and fatigue (35%). A majority (84%) lacked confidence to recognize AF, and 58% were not sure when they should seek care for AF symptoms. Nearly a third (32%) believed palpitations are always present with AF, and 74% believed that low energy would not be their only symptom of AF. Higher scores for AF Symptom Knowledge ( p = .02) were observed in females, and General Knowledge about AF was greater for younger participants ( p < .001). Participants lacked knowledge and confidence to aid decision-making for treatment-seeking for symptoms of AF and held inaccurate beliefs about AF that could hinder early treatment-seeking. Programs to promote AF awareness should explain the spectrum of symptoms that may be manifested by AF and include action plans for responding to symptoms.
Graduate medical education competencies for international health electives: A qualitative study
Nordhues, Hannah C. , Bashir, Majid , Merry, Stephen , Sawatsky, Adam P. , Bashir, M Usmaan, Merry, Stephen P, Merry, Stephen P

Mayo Clinic

Medical Teacher | August 29, 2017 | Volume: 39 | Issue: 11 | Pages: 1128-1137

10.1080/0142159x.2017.1361518 | PMID 28847185 Get It

Relamorelin for the treatment of gastrointestinal motility disorders
Chedid, Victor , Camilleri, Michael , Chedid, Victor G

Mayo Clinic

Expert Opinion on Investigational Drugs | August 29, 2017 | Volume: 26 | Issue: 10 | Pages: 1189-1197

10.1080/13543784.2017.1373088 | PMID 28847163 Get It

Road Map for Research Training in the Residency Learning Experience
Personett, Heather A. , Frazee, Erin N., Skrupky, Lee P. , Johnson, Thomas J., Schramm, Garrett E. , Hammond, Drayton A , Frazee, Erin N., Skrupky, Lee P

Mayo Clinic

Journal of Pharmacy Practice | August 29, 2017 | Volume: 31 | Issue: 5 | Pages: 489-496

10.1177/0897190017727382 | PMID 28847231 Get It

The American Society of Health-System Pharmacists residency accreditation standards require all postgraduate residency training programs to teach and evaluate a resident’s ability to advance practice through project development and presentation, underscoring the importance of conducting research in today’s professional climate. Although many residents express strong interest in research participation and contributing to the medical literature, many obstacles to publication have been identified. We aim to illustrate a deliberate approach to teaching this material and structuring the longitudinal experience in a way that maximizes resources to overcome these barriers. Such efforts should aid residents, advisors, and program directors in establishing curriculum which leads to successful completion and publication of pharmacy resident’s research projects.
Facilitating Treatment Adherence in Pain Medicine
Wilson, Peter R, Wilson, Peter R

Mayo Clinic

Pain Medicine | August 29, 2017 | Volume: 19 | Issue: 6 | Pages: 1290-1292

10.1093/pm/pnx218 Get It

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Moreau, Philippe , Chanan‐Khan, Asher , Roberts, Andrew W. , Agarwal, Amit B., Kumar, Shaji , Touzeau, Cyrille , Punnoose, Elizabeth A. , Cordero, Jaclyn, Munasinghe, Wijith, Jia, Jia , Salem, Ahmed Hamed , Freise, Kevin J. , Enschede, Sari H., Maciag, Paulo , Verdugo, Maria, Roberts, Andrew W , Moreau, Philippe , Touzeau, Cyrille , Facon, Thierry T.F. , Leverson, Joel D. , Ross, Jeremy A. , Harrison, Simon J , Salem, Ahmed Hamed

Mayo Clinic

Blood | August 29, 2017 | Volume: 130 | Issue: 22 | Pages: 2392-2400

10.1182/blood-2017-06-788323 | PMID 28847998 Get It

Key Points In relapsed/refractory MM, venetoclax plus bortezomib and dexamethasone appears to be safe and efficacious. This is a novel therapeutic approach for MM.
Esthesioneuroblastoma and Olfactory Preservation: Is it Reasonable to Attempt Smell Preservation?
Janus, Jeffrey R. , Hughes, Joshua , Stokken, Janalee K., Moore, Eric J. , Ryan, Tarek, Link, Michael J. , Hughes, Joshua D, Gompel, Jamie J. Van , Price, Daniel L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | August 28, 2017 | Volume: 79 | Issue: 02 | Pages: 184-188

10.1055/s-0037-1606307 | PMID 29868325 Get It

Objective Olfactory preservation after resection of esthesioneuroblastoma (ENB) has been reported, however, the ability to predict tumor involvement of the olfactory system is critical to this surgical strategy. This study aims to answer the question: Can a surgeon predict, based on preoperative imaging, whether there is unilateral involvement of the olfactory system allowing for safe attempt of olfactory preservation? Methods This is a retrospective review of post-resection ENB meeting inclusion criteria of having bilateral olfactory tracts and bulbs submitted at the time of primary resection for pathologic margins. Five board-certified skull base surgeons blinded to the pathology individually reviewed the preoperative MRI scans to predict degree of tumor involvement. Results Olfactory bulb involvement occurred in both bulbs in 35% of cases and unilateral in 39% of cases, and there was no involvement in 26% of cases sampled. When comparing physician prediction of involved tracts or bulbs, involvement was appropriate or over-called (i.e., called positive when pathology was in fact negative) in 96% of cases. Conclusion This study demonstrates unilateral or no pathologic olfactory involvement of the olfactory system in 65% of cases. Our ability to predict this involvement, which may allow for a management strategy that attempts to preserve olfactory function, was accurate at 96%. Therefore, interpretation of imaging and proceeding with smell preservation in ENB appears reasonable in this cohort.Level of Evidence: Level 2b.